Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New study tests if better imaging during stent surgery improves heart outcomes

NCT ID NCT05493904

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 28, 2026 · Updated 1 time

Summary

This study looks at 320 people with complex coronary artery disease who need a stent. It compares using a special camera (OCT) versus standard X-ray (angiography) to guide the stent placement. The goal is to see which method leads to better blood flow after the procedure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

320 people

The number who actually took part.

Started

Nov 2022

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients \>18 years old 2. Patients with stable or unstable angina and complex coronary lesions\* 3. Patients who were indicated revascularization * Diameter stenosis \>90% by angiography * Diameter stenosis with 50\~90% with pre-interventional FFR ≤0.80 4. Patients who underwent implantation of 2nd generation drug-eluting stent * Definitions of complex coronary lesions 1. True bifurcation lesion (Medina 1,1,1/1,0,1/0,1,1) with side branch ≥2.5mm size 2. Chronic total occlusion (≥3 months) as target lesion 3. PCI for unprotected left main (LM) disease (LM os, body, distal LM bifurcation including non-true bifurcation) 4. Long coronary lesions (implanted stent ≥38 mm in length) 5. Multi-vessel PCI (≥2 major epicardial coronary arteries treated at one PCI session) 6. Multiple stents needed (≥3 more stent per patient) 7. In-stent restenosis lesion as target lesion 8. Severely calcified lesion (encircling calcium in angiography) 9. Left anterior descending (LAD), left circumflex artery (LCX), and right coronary artery (RCA) ostial lesion Exclusion Criteria: 1. Target lesions not amenable for PCI by operators' decision 2. Cardiogenic shock (Killip class IV) at presentation 3. Less than TIMI 3 flow of target vessel after index procedure 4. Intolerance to Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Heparin, Everolimus, Zotarolimus, Biolimus, or Sirolimus 5. Known true anaphylaxis to contrast medium (not allergic reaction but anaphylactic shock) 6. Renal insufficiency such that an additional contrast medium would be harmful for patient 7. Recent ST-segment elevation myocardial infarction (STEMI) 8. Inability to receive adenosine or nicorandil injection 9. Pregnancy or breast feeding 10. Non-cardiac co-morbid conditions are present with life expectancy \<2 year or that may result in protocol non-compliance (per site investigator's medical judgment) 11. Unwillingness or inability to comply with the procedures described in this protocol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Angina pectoris are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Chonnam National University Hospital

    Gwangju, 61469, South Korea

  • Chung-Ang University Gwangmyeong Hospital

    Gwangmyeong, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.